Haase, Detlef

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:50:35Z"],["dc.date.available","2018-11-07T09:50:35Z"],["dc.date.issued","2015"],["dc.format.extent","32"],["dc.identifier.isi","000364268800068"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35736"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Evolution of chromosome 7 material loss in myeloid malignancies"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","161"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","BioTechniques"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Reins, Jana"],["dc.contributor.author","Mossner, Maximilian"],["dc.contributor.author","Richter, Lennart"],["dc.contributor.author","Kmetsch, Anke"],["dc.contributor.author","Thiel, Eckhard"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.date.accessioned","2018-11-07T08:58:28Z"],["dc.date.available","2018-11-07T08:58:28Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.2144/000113612"],["dc.identifier.isi","288639300010"],["dc.identifier.pmid","21486236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23649"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biotechniques Office"],["dc.relation.issn","0736-6205"],["dc.title","Whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Hildebrandt, B."],["dc.contributor.author","Symeonidis, Argiris"],["dc.contributor.author","Cermak, J."],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, T."],["dc.contributor.author","Sekkeres, M."],["dc.contributor.author","Maciejewski, Andrzej J."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Seymour, J."],["dc.contributor.author","Kenealy, M."],["dc.contributor.author","Koeppler, H."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Blum, S."],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Kreuzer, Karl Anton"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Kuendgen, A."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.date.accessioned","2018-11-07T08:30:27Z"],["dc.date.available","2018-11-07T08:30:27Z"],["dc.date.issued","2009"],["dc.format.extent","S74"],["dc.identifier.isi","000266759600107"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16895"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Symposium on Myelodysplastic Syndromes"],["dc.relation.eventlocation","Patras, GREECE"],["dc.relation.issn","0145-2126"],["dc.title","Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","248"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Westhofen, Gina"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Al-Ali, Haifa Kathrin"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:34:16Z"],["dc.date.available","2018-11-07T09:34:16Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900606"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32140"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Iron overload-induced genetic instability in myelodysplastic syndromes"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","254"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal Of Haematology"],["dc.bibliographiccitation.lastpage","256"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Steuernagel, Peter"],["dc.contributor.author","Shirneshan, Katayoo"],["dc.contributor.author","Baesecke, Joerg"],["dc.date.accessioned","2018-11-07T09:52:53Z"],["dc.date.available","2018-11-07T09:52:53Z"],["dc.date.issued","2015"],["dc.description.abstract","A 62-yr-old man with two healthy daughters was diagnosed with osteomyelofibrosis. To our surprise, a female XX-karyotype was observed in bone marrow and confirmed in PHA-stimulated T-lymphocytes from peripheral blood. Further molecular genetic investigation revealed a submicroscopic translocation between the short arm of X and Y, which leads to an XX-male genotype based on an unbalanced translocation X;Y. This rare coincidence was further accentuated as the USP9Y gene, suspected to be to be involved in sperm cell production, was absent, but no azoospermia was present. In general, routine cytogenetics may result in findings that need to be further delineated and, as here, lead to a rare observation."],["dc.identifier.doi","10.1111/ejh.12555"],["dc.identifier.isi","000359600500009"],["dc.identifier.pmid","25808090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36217"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1600-0609"],["dc.relation.issn","0902-4441"],["dc.title","Primary osteomyelofibrosis and an XX-male genotype"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4642"],["dc.bibliographiccitation.issue","30"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","4648"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Doehner, Konstanze"],["dc.contributor.author","Mack, Silja"],["dc.contributor.author","Stoppel, Michael"],["dc.contributor.author","Kiraly, Franz"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Hartmann, Frank"],["dc.contributor.author","Horst, Heinz-August"],["dc.contributor.author","Koller, Elisabeth"],["dc.contributor.author","Petzer, Andreas L."],["dc.contributor.author","Grimminger, Wolfgang"],["dc.contributor.author","Kobbe, Guido"],["dc.contributor.author","Glasmacher, Axel"],["dc.contributor.author","Salwender, Hans"],["dc.contributor.author","Kirchen, Heinz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Kremers, Stephan"],["dc.contributor.author","Matzdorff, Axel C."],["dc.contributor.author","Benner, Axel"],["dc.contributor.author","Doelmer, Hartmut"],["dc.date.accessioned","2018-11-07T08:38:34Z"],["dc.date.available","2018-11-07T08:38:34Z"],["dc.date.issued","2010"],["dc.description.abstract","Purpose To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and matched unrelated donors (MUDs) on outcome in high-risk patients with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. Patients and Methods Between 1998 and 2004, 844 patients (median age, 48 years; range, 16 to 62 years) with AML were enrolled onto protocol AMLHD98A that included a risk-adapted treatment strategy. High risk was defined by the presence of unfavorable cytogenetics and/or by no response to induction therapy. Results Two hundred sixty-seven (32%) of 844 patients were assigned to the high-risk group. Of these 267 patients, 51 patients (19%) achieved complete remission but had adverse cytogenetics, and 216 patients (81%) had no response to induction therapy. Allogeneic HSCT was actually performed in 162 (61%) of 267 high-risk patients, after a median time of 147 days after diagnosis. Graft sources were as follows: MRD (n = 62), MUD (n = 89), haploidentical donor (n = 10), and cord blood (n = 1). The 5-year overall survival rates were 6.5% (95% CI, 3.1% to 13.6%) for patients (n = 105) not proceeding to HSCT and 25.1% (95% CI, 19.1% to 33.0%; from date of transplantation) for patients (n = 162) receiving HSCT. Multivariable analysis including allogeneic HSCT as a time-dependent covariable revealed that allogeneic HSCT significantly improved outcome; there was no difference in outcome between allogeneic HSCT from MRD and MUD. Conclusion Allogeneic HSCT in younger adults with high-risk AML has a significant beneficial impact on outcome, and allogeneic HSCT from MRD and MUD yields similar results."],["dc.identifier.doi","10.1200/JCO.2010.28.6856"],["dc.identifier.isi","000283056400034"],["dc.identifier.pmid","20805454"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18796"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","820"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","829"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Luno, Elisa"],["dc.contributor.author","Cervera, Jose"],["dc.contributor.author","Granada, Isabel"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Faderl, Stefan"],["dc.contributor.author","Pierce, Sherry"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:12:21Z"],["dc.date.available","2018-11-07T09:12:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of abnormalities has increased substantially. The present study proposes a new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients. Patients and Methods Patients were included from the German-Austrian MDS Study Group (n = 1,193), the International MDS Risk Analysis Workshop (n = 816), the Spanish Hematological Cytogenetics Working Group (n = 849), and the International Working Group on MDS Cytogenetics (n = 44) databases. Patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. Internal validation by bootstrap analysis and external validation in an independent patient cohort were performed to confirm the results. Results In total, 19 cytogenetic categories were defined, providing clear prognostic classification in 91% of all patients. The abnormalities were classified into five prognostic subgroups (P < .001): very good (median OS, 61 months; hazard ratio [HR], 0.5; n = 81); good (49 months; HR, 1.0 [reference category]; n = 1,809); intermediate (26 months; HR, 1.6; n = 529); poor (16 months; HR, 2.6; n = 148); and very poor (6 months; HR, 4.2; n = 187). The internal and external validations confirmed the results of the score. Conclusion In conclusion, these data should contribute to the ongoing efforts to update the IPSS by refining the cytogenetic risk categories. J Clin Oncol 30: 820-829. (C) 2012 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2011.35.6394"],["dc.identifier.isi","000302626600017"],["dc.identifier.pmid","22331955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26930"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1747"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","1758"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Stevenson, Kristen E."],["dc.contributor.author","Neuberg, Donna"],["dc.contributor.author","Maciejewski, Jaroslaw P."],["dc.contributor.author","Nazha, Aziz"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Ebert, Benjamin L."],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Haferlach, Claudia"],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Kern, Wolfgang"],["dc.contributor.author","Ogawa, Seishi"],["dc.contributor.author","Nagata, Yasunobu"],["dc.contributor.author","Yoshida, Kenichi"],["dc.contributor.author","Graubert, Timothy A."],["dc.contributor.author","Walter, Matthew J."],["dc.contributor.author","List, Alan F."],["dc.contributor.author","Komrokji, Rami S."],["dc.contributor.author","Padron, Eric"],["dc.contributor.author","Sallman, David"],["dc.contributor.author","Papaemmanuil, Elli"],["dc.contributor.author","Campbell, Peter J."],["dc.contributor.author","Savona, Michael R."],["dc.contributor.author","Seegmiller, Adam"],["dc.contributor.author","Adès, Lionel"],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Shih, Lee-Yung"],["dc.contributor.author","Bowen, David"],["dc.contributor.author","Groves, Michael J."],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Fontenay, Michaela"],["dc.contributor.author","Kosmider, Olivier"],["dc.contributor.author","Bar-Natan, Michal"],["dc.contributor.author","Steensma, David"],["dc.contributor.author","Stone, Richard"],["dc.contributor.author","Heuser, Michael"],["dc.contributor.author","Thol, Felicitas"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Karsan, Aly"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Hellström-Lindberg, Eva"],["dc.contributor.author","Boultwood, Jacqueline"],["dc.contributor.author","Pellagatti, Andrea"],["dc.contributor.author","Santini, Valeria"],["dc.contributor.author","Quek, Lynn"],["dc.contributor.author","Vyas, Paresh"],["dc.contributor.author","Tüchler, Heinz"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bejar, Rafael"],["dc.date.accessioned","2020-12-10T18:09:34Z"],["dc.date.available","2020-12-10T18:09:34Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1038/s41375-018-0351-2"],["dc.identifier.eissn","1476-5551"],["dc.identifier.issn","0887-6924"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16447"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73694"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","198"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Nolte, F."],["dc.contributor.author","Hoechsmann, B."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Lueck, A."],["dc.contributor.author","Gattermann, Norbert"],["dc.contributor.author","Taupitz, Matthias"],["dc.contributor.author","Baier, M."],["dc.contributor.author","Leismann, O."],["dc.contributor.author","Junkes, A."],["dc.contributor.author","Schumann, Christian"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schrezenmeier, Hubert"],["dc.date.accessioned","2018-11-07T09:30:38Z"],["dc.date.available","2018-11-07T09:30:38Z"],["dc.date.issued","2013"],["dc.description.abstract","The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (+/- 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (+/- 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (a parts per thousand yenaEuro parts per thousand 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations."],["dc.identifier.doi","10.1007/s00277-012-1594-z"],["dc.identifier.isi","000313445100007"],["dc.identifier.pmid","23073603"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31353"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Deitken, Sven"],["dc.contributor.author","Seraphin, Joerg"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Bruemmendorf, Tim Henrik"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Boehme, Angelika"],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T08:36:46Z"],["dc.date.available","2018-11-07T08:36:46Z"],["dc.date.issued","2010"],["dc.format.extent","1211"],["dc.identifier.isi","000289662203269"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18387"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]